Jennings Lance C, Monto Arnold S, Chan Paul K S, Szucs Thomas D, Nicholson Karl G
Microbiology Department, Canterbury Health Laboratories, University of Otago, Christchurch, New Zealand.
Lancet Infect Dis. 2008 Oct;8(10):650-8. doi: 10.1016/S1473-3099(08)70232-9.
The history of pandemic influenza, along with the evolving epizootic of the highly pathogenic avian influenza A (H5N1) virus and the severity of associated human infections, serve as a warning to the world of the threat of another influenza pandemic. Conservative estimates suggest that up to 350 million people could die and many more would be affected, causing disruption to health-care systems, society, and the world's economy. WHO has encouraged countries to prepare in advance by developing influenza pandemic preparedness plans that involve public-health and pharmaceutical interventions. Vaccination is a cornerstone of these plans; however, a pandemic vaccine cannot be manufactured in advance because the next pandemic virus cannot be predicted. The concepts of vaccine stockpiling and prepandemic vaccination have thus become attractive. Human H5N1 vaccines are currently available and can induce heterotypic immunity. WHO and governments should give urgent consideration to the use of these vaccines for the priming of individuals or communities who would be at greatest risk of infection if an H5N1 influenza pandemic were to emerge.
大流行性流感的历史,连同高致病性甲型禽流感(H5N1)病毒不断演变的动物疫情以及相关人类感染的严重性,向世界发出了另一场流感大流行威胁的警告。保守估计表明,多达3.5亿人可能死亡,更多的人会受到影响,这将对医疗保健系统、社会和世界经济造成破坏。世卫组织鼓励各国提前做好准备,制定包括公共卫生和药物干预措施的流感大流行防范计划。疫苗接种是这些计划的基石;然而,大流行疫苗无法提前生产,因为无法预测下一种大流行病毒。因此,疫苗储备和大流行前疫苗接种的概念变得具有吸引力。目前已有人类H5N1疫苗,且能诱导异型免疫。世卫组织和各国政府应紧急考虑使用这些疫苗,对如果H5N1流感大流行出现将面临最大感染风险的个人或社区进行预接种。